FGFR2 Gene Rearrangement: Clinical Trials

1 recruiting, 1 terminated. 2 Phase 2.

By phase and status

Phase	Trials	Status
Phase 2	2	Recruiting 1, Terminated 1

Follow FGFR2 Gene Rearrangement: new trials by email Literature Review of FGFR2 Gene Rearrangement trials Research Report on FGFR2 Gene Rearrangement

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement Pemigatinib, Durvalumab - Intrahepatic Cholangiocarcinoma, FGFR2 Gene Rearrangement	Phase 2	Recruiting	Mehmet Akce	38	2026-01-27	2026-10-05
Pemigatinib After Curative Local Therapy in Advanced iCCA With FGFR2 Fusion/Rearrangements Pemigatinib - Intrahepatic Cholangiocarcinoma, FGFR2 Gene Mutation	Phase 2	Terminated	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest	2	2022-11-11	2025-04-13

Narrower conditions

Cholangiocarcinoma (2)

Broader conditions

Adenocarcinoma (2)  ·  Carcinoma (2)  ·  Neoplasms (2)  ·  Neoplasms by Histologic Type (2)  ·  Neoplasms, Glandular and Epithelial (2)

Interventions

pemigatinib (2)  ·  durvalumab (1)

Sponsors

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest (1)  ·  Mehmet Akce (1)

Countries

Germany (1)  ·  United States (1)

Top investigators

Mehmet Akce, MD (1)  ·  Salah-Eddin Al-Batran, Prof. Dr. (1)  ·  Thorsten Goetze, Prof. Dr. (1)